Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults with Early Alzheimer’s Disease
In April 2026, a Phase III clinical trial published in The Lancet evaluated crenezumab, an anti-amyloid monoclonal antibody, in adults with early Alzheimer’s disease, finding no significant slowing of cognitive ... Read More